Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040)
South Korea · Delayed Price · Currency is KRW 5,670.00
+80.00 (1.43%)
At close: Jan 23, 2026
Kyung Dong Pharmaceutical Revenue
Kyung Dong Pharmaceutical had revenue of 48.88B KRW in the quarter ending September 30, 2025, a decrease of -1.51%. This brings the company's revenue in the last twelve months to 193.64B, up 2.35% year-over-year. In the year 2024, Kyung Dong Pharmaceutical had annual revenue of 193.94B with 19.22% growth.
Revenue (ttm)
193.64B
Revenue Growth
+2.35%
P/S Ratio
0.79
Revenue / Employee
553.25M
Employees
350
Market Cap
152.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 193.94B | 31.26B | 19.22% |
| Dec 31, 2023 | 162.67B | -20.04B | -10.97% |
| Dec 31, 2022 | 182.72B | 5.11B | 2.88% |
| Dec 31, 2021 | 177.61B | 3.78B | 2.18% |
| Dec 31, 2020 | 173.83B | -2.67B | -1.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DongKoo Bio & Pharma | 238.39B |
| GREEN CROSS WellBeing | 151.06B |
| HYUNDAI BIOLAND | 129.68B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 102.11B |
| KOREA PHARMA | 90.11B |
| OPTUS Pharmaceutical | 87.58B |
| High Tech Pharm | 75.60B |
| Vivozon Pharmaceutical | 66.40B |